Semaglutide Accepted in Scotland for Heart Risk Reduction

Semaglutide accepted in Scotland gives NHS clinicians Wegovy for adults with heart disease and BMI 27+, but access hinges on local pathways.

Ishan Crawford 6 hours ago 0 5

Semaglutide has been accepted in Scotland for cardiovascular risk reduction in adults with established cardiovascular disease and a body mass index of 27 or higher, giving NHS Scotland clinicians access to Wegovy as a weekly injection alongside diet and exercise to lower the risk of cardiovascular death, non-fatal heart attack or non-fatal stroke.

The Scottish Medicines Consortium advice, published on 08 June 2026, moves a medicine known to many patients as a weight-loss injection into secondary cardiovascular prevention. The harder question now sits with NHS Boards: which service owns prescribing when a drug belongs to obesity care, cardiology and long-term risk management at the same time?

The SMC Decision Moves Wegovy Into Heart Prevention

The Scottish Medicines Consortium (SMC, the body that advises NHS Scotland on newly licensed medicines) accepted semaglutide, sold by Novo Nordisk as Wegovy, after a full submission. The indication covers adults with established cardiovascular disease (CVD, disease affecting the heart or blood vessels) and a BMI of 27 or higher.

SMC’s wording keeps the treatment tied to a reduced-calorie diet and increased physical activity. It also limits the acceptance to major adverse cardiovascular events (MACE, a composite measure that includes cardiovascular death, non-fatal myocardial infarction and non-fatal stroke).

Semaglutide will provide a useful treatment option to help reduce major cardiovascular events in patients who are overweight and have cardiovascular disease.

Dr Rob Peel, chair of SMC, said that in the consortium’s June decisions release. The sentence is short, but it changes the clinical filing cabinet Wegovy sits in. This decision is about patients who have already had heart or vascular disease, where the aim is to prevent another event.

semaglutide accepted in Scotland heart risk reduction

SELECT Put a Heart Outcome on the Label

The evidence base comes from SELECT, a phase 3 cardiovascular outcomes trial in adults with overweight or obesity and established CVD but no diabetes history. The SELECT trial report in the New England Journal of Medicine enrolled 17,604 people aged 45 or older and tested once-weekly semaglutide 2.4 mg against placebo on top of standard cardiovascular care.

17,604 participants were randomised across the trial.
6.5% versus 8.0% was the primary MACE result for semaglutide and placebo.
20% relative risk reduction was reported for the primary composite endpoint, with a hazard ratio of 0.80.
9.4% body-weight fall at 104 weeks was recorded with semaglutide, compared with 0.9% with placebo.

Those patients were already receiving standard cardiovascular care, including medicines for blood pressure and cholesterol where appropriate. American College of Cardiology trial summaries report that 88% of participants were on statin therapy, which matters because the benefit was measured in a treated population, not in a group starting from minimal care.

Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1, a hormone pathway involved in appetite, insulin and glucagon signalling). The cardiovascular mechanism is still being studied. SELECT recorded weight loss, lower blood pressure and fewer new diabetes-range glycated haemoglobin readings, but the trial was designed around hard cardiovascular outcomes.

Who Qualifies in Scotland?

SMC’s public summary says semaglutide is available for prescribing on the NHS in Scotland for the accepted use, with clinician judgement still deciding whether it suits an individual patient. The language is broad enough to include people with prior heart attack, stroke or symptomatic peripheral arterial disease, provided the BMI threshold is met.

Established disease means the patient already has cardiovascular disease, so this is secondary prevention.
BMI threshold starts at 27 kg/m2, covering overweight and obesity categories.
Adjunct use means the injection sits alongside diet, activity and standard heart medicines.
Event target is cardiovascular death, non-fatal myocardial infarction or non-fatal stroke.

This is a different route from Scotland’s earlier SMC acceptance of Wegovy for weight management. The older SMC weight-management advice for Wegovy restricted use to patients with a BMI of at least 30 and at least one weight-related comorbidity, with treatment in specialist weight management services.

The new use starts from cardiovascular disease. That puts cardiology clinics, lipid services, stroke follow-up, vascular teams, GPs and weight management services into the same prescribing conversation.

The Safety Profile Starts With Tolerability

The main caution in SELECT was discontinuation. The American College of Cardiology summary reports adverse events leading to trial-drug discontinuation in 16.6% of semaglutide patients, compared with 8.2% on placebo. Gastrointestinal complications accounted for 10.0% of discontinuations with semaglutide and 2.0% with placebo.

SELECT Safety Measure	Semaglutide	Placebo
All serious adverse events	33.4%	36.4%
Adverse events leading to stopping trial drug	16.6%	8.2%
Gastrointestinal complications leading to stopping	10.0%	2.0%
Acute pancreatitis	0.2%	0.3%
Acute kidney failure	1.9%	2.3%

The UK Wegovy Summary of Product Characteristics sets out gradual dose escalation to reach the 2.4 mg once-weekly maintenance dose. Treatment begins at 0.25 mg weekly and rises in steps over 16 weeks, a schedule designed to reduce gastrointestinal symptoms during initiation.

That dosing pattern turns the first months into a practical test of persistence and support. Patients with heart disease often take several long-term medicines already, so nausea, diarrhoea, constipation and dose changes have to be handled without disrupting proven cardiovascular therapy.

NHS Access Depends on Local Pathways

SMC acceptance does not write the clinic rota. The advice applies in the context of an approved Patient Access Scheme (PAS, a confidential discount arrangement used to reach the cost-effectiveness case), or list prices that deliver equivalent or lower cost-effectiveness results.

England moved first on the same cardiovascular indication. The NICE TA1152 recommendation for semaglutide, published on 07 May 2026, says semaglutide can be used within its marketing authorisation for adults with established CVD and BMI of at least 27, subject to the company providing it under the commercial arrangement.

Authority	Decision	Access Condition
SMC, Scotland	Accepted for NHS Scotland on 08 June 2026	Approved PAS terms or equivalent pricing
NICE, England	Recommended in TA1152	Commercial arrangement and routine NHS funding route
FDA, United States	Approved cardiovascular risk-reduction indication in March 2024	Use with reduced-calorie diet and increased physical activity

The U.S. Food and Drug Administration (FDA, the American medicines regulator) had already described Wegovy as the first weight-loss medication approved to help prevent life-threatening cardiovascular events in adults with CVD and overweight or obesity in its Wegovy cardiovascular approval announcement.

Capacity in Scotland was under pressure before this new indication. CN Media previously covered Scotland pharmacies’ call for an NHS weight-loss drug service, where Community Pharmacy Scotland argued for a wider role in safe access to obesity medicines. A separate Scottish pharmacies campaign on obesity medicines pushed the same local-access question toward ministers.

Scotland’s Risk Pool Is Large

Cardiovascular disease is already a national prevention target. The NHS Scotland Right Decisions platform says in its national cardiovascular disease toolkit that CVD causes more than a quarter of all deaths in Scotland and is the second most common cause of death after cancer.

The same toolkit says Scotland is predicting a 21% rise in disease burden by 2043, with obesity linked to the increase. That is the backdrop for a medicine that reaches patients through a BMI threshold but is being used to reduce recurrent cardiovascular events.

The Scottish Health Survey 2024 summary reported that 31% of adults were living with obesity in 2024, similar to 32% in 2023. It also reported a mean adult BMI of 28.1 kg/m2, up from 27.1 kg/m2 in 2003.

Those population figures do not estimate how many Scots will qualify for semaglutide under the new cardiovascular indication. The eligible group is narrower: adults with existing CVD, BMI of at least 27 and clinical suitability for a GLP-1 medicine. It is still big enough to make pathway design a budget and workforce issue, not a niche prescribing footnote.

The Service Design Choice Is Now in Front of NHS Boards

Secondary prevention in Scotland already includes smoking cessation, blood-pressure control, lipid-lowering treatment, antiplatelet therapy where indicated, diet, physical activity and cardiac rehabilitation. Semaglutide now joins that list for a defined group, with SMC acceptance giving clinicians another licensed option rather than replacing established care.

The immediate work is practical. Boards need referral criteria, prescribing ownership, adverse-effect counselling, review points and a clear hand-off between specialists and primary care. Pharmacists need to know how dose escalation will be monitored. Patients need plain guidance on what benefit was measured in SELECT and why side effects can lead some people to stop treatment.

For Novo Nordisk, the Scottish decision adds another health-system endorsement to the cardiovascular use of Wegovy. For NHS Scotland, the acceptance turns a trial result into a service planning problem that starts with the next eligible patient in clinic.

Disclaimer: This article is for informational purposes only and does not provide medical advice. Semaglutide carries risks and suitability depends on individual medical history, current medicines and monitoring needs. Patients should consult a qualified clinician or pharmacist. Figures and guidance are accurate as of 09 June 2026.